These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28612614)

  • 1. [Malignant Melanoma - from Classical Histology towards Molecular Genetic Testing].
    Ryška A; Horký O; Berkovcová J; Tichá I; Kalinová M; Matějčková M; Bóday Á; Drábek J; Martínek P; Šimová J; Sieglová K; Vošmiková H
    Klin Onkol; 2017; 30(3):182-189. PubMed ID: 28612614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology of melanoma.
    Elder DE
    Surg Oncol Clin N Am; 2015 Apr; 24(2):229-37. PubMed ID: 25769708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers].
    Müllerová Z; Müller T; Křivánková K; Vojtěšek B; Müller P
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):46-53. PubMed ID: 27846720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant Melanomas of the Skin Arising on the Feet.
    Bartoš V; Kullová M
    Klin Onkol; 2018; 31(4):289-292. PubMed ID: 30541312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BRAF mutation testing for the choice of melanoma treatment].
    Imianitov EN
    Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma.
    Pejkova S; Dzokic G; Tudzarova-Gjorgova S; Panov S
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016 Nov; 37(2-3):89-97. PubMed ID: 27883322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras, Raf, and MAP kinase in melanoma.
    Solus JF; Kraft S
    Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction.
    Lewis TB; Robison JE; Bastien R; Milash B; Boucher K; Samlowski WE; Leachman SA; Dirk Noyes R; Wittwer CT; Perreard L; Bernard PS
    Cancer; 2005 Oct; 104(8):1678-86. PubMed ID: 16116595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular pathology of cutaneous melanoma.
    Bogenrieder T; Herlyn M
    Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.